TITLE PAGE

Type of article: Research article

Full-length title:

Culture and identification of a "Deltamicron" SARS-CoV-2 in a three cases cluster in

southern France

Short title (for the running head): Emergence of a SARS-CoV-2 Delta/Omicron

recombinant

Author list: Philippe COLSON[1,2,3] *, Pierre-Edouard FOURNIER[1,2,4], Jeremy

DELERCE[1], Matthieu MILLION[1,2,3], Marielle BEDOTTO[1], Linda HOUHAMDI[1],

Nouara YAHI[5], Jeremy BAYETTE[6], Anthony LEVASSEUR[1,2], Jacques FANTINI[5],

Didier RAOULT[1,2], Bernard LA SCOLA[1,2,3] *

Affiliations: [1] IHU Méditerranée Infection, 19-21 boulevard Jean Moulin, 13005 Marseille,

France; [2] Aix-Marseille Univ., Institut de Recherche pour le Développement (IRD), Microbes

Evolution Phylogeny and Infections (MEPHI), 27 boulevard Jean Moulin, 13005 Marseille,

France; [3] Assistance Publique-Hôpitaux de Marseille (AP-HM), 264 rue Saint-Pierre, 13005

Marseille, France; [4] Aix-Marseille Univ., Institut de Recherche pour le Développement (IRD),

Vecteurs – Infections Tropicales et Méditerranéennes (VITROME), 27 boulevard Jean

Moulin, 13005 Marseille, France; [5] Aix-Marseille Université, INSERM UMR S 1072, 51

boulevard Pierre Dramard, 13015 Marseille, France; [6] LBM Inovie Labosud, 90 rue Nicolas

Chedville, 34070, Montpellier, France.

* Corresponding author: Bernard La Scola, IHU Méditerranée Infection, 19-21 boulevard

Jean Moulin, 13005 Marseille, France. Tel.: +33 413 732 401, Fax: +33 413 732 402; email:

bernard.la-scola@univ-amu.fr; Philippe Colson, IHU Méditerranée Infection, 19-21

boulevard Jean Moulin, 13005 Marseille, France. Tel.: +33 413 732 401, Fax: +33 413 732

402; email: philippe.colson@univ-amu.fr

Key words: SARS-CoV-2; recombinant; variant; lineage; Delta; Omicron; Deltamicron; epidemic

Word counts: abstract, 180; text, 2,364

Figures: 3; **Table:** 1; **References:** 47

ABSTRACT

Multiple SARS-CoV-2 variants have successively, or concommitantly spread

worldwide since summer 2020. A few co-infections with different variants were reported and

genetic recombinations, common among coronaviruses, were reported or suspected based on

co-detection of signature mutations of different variants in a given genome. Here we report

three infections in southern France with a Delta 21J/AY.4-Omicron 21K/BA.1 "Deltamicron"

recombinant. The hybrid genome harbors signature mutations of the two lineages, supported

by a mean sequencing depth of 1,163-1,421 reads and mean nucleotide diversity of 0.1-0.6%.

It is composed of the near full-length spike gene (from codons 156-179) of an Omicron

21K/BA.1 variant in a Delta 21J/AY.4 lineage backbone. Importantly, we cultured an isolate

of this recombinant and sequenced its genome. It was observed by scanning electron

microscopy. As it is misidentified with current variant screening qPCR, we designed and

implemented for routine diagnosis a specific duplex qPCR. Finally, structural analysis of the

recombinant spike suggested its hybrid content could optimize viral binding to the host cell

membrane. These findings prompt further studies of the virological, epidemiological, and

clinical features of this recombinant.

TEXT

Introduction

The current SARS-CoV-2 pandemic has highlighted since the summer of 2020 the successive or concomittant emergence of numerous viral variants, each causing a specific epidemic.[1-3] Some of these variants spread to become pandemic while others remained epidemic in a restricted geographical area. The variants characterized so far have been shaped by nucleotide substitutions, insertions or deletions. However, another major evolutionary mechanism of RNA viruses is genetic recombination, which is very common among coronaviruses.[4-8] It requires co-infection of the same host cell by two viruses, which may be two distinct mutants or variants.[9] Therefore, the frequency of creation of recombinants between two variants depends on the duration of their co-circulation, on the time until viral clearance, and on the number of people exposed to both viruses. Co-infections with two variants were reported including recently with SARS-CoV-2 Delta and Omicron variants.[10-13] Furthermore, genetic recombinations were reported or suspected, based on the concurrent detection in consensus genomes of signature mutations of different mutants or variants.[10,12,14-24] A study detected up to 1,175 (0.2%) putative recombinant genomes among 537,360 genomes and estimated that up to 5% SARS-CoV-2 having circulated in the USA and UK could be recombinants.[16]

Two pandemic variants, Delta and Omicron 21K (Nextclade classification[25,26])/BA.1 (Pangolin classification[27]), recently succeeded each other as the predominant viruses but co-circulated for a period of several weeks, creating conditions for co-infections and subsequently recombinations. This period spanned between December 27th, 2021 and February 14th, 2022 in our geographical area, as assessed by our SARS-CoV-2 genotypic surveillance based on variant-specific qPCR and next-generation genomic sequencing.[3,28,29] In

January 2022, genomes harboring mutations from both Delta and Omicron 21K/BA.1 variants

were reported in Cyprus but it was questioned whether sequences might have resulted from

contamination.[23] Still, 15 genomes as of 27/02/2022 being hybrids of these two variants and

highly similar between each other were reported since February 2022 (https://github.com/cov-

lineages/pango-designation/issues/444). We herein report three infections by a recombinant

SARS-CoV-2 Delta 21K/AY.4-Omicron 21K/BA.1 whose genome is highly similar to the 15

previously reported genomes and the isolation of the recombinant virus from one of the

patients.

Materials and methods

Nasopharyngeal samples were collected from two patients in our university hospital

institute (Méditerranée Infection; https://www.mediterranee-infection.com/) and tested for

SARS-CoV-2 infection by real-time reverse transcription-PCR (qPCR) as previously

described.[3,28,29] The third patient was sampled in a private medical biology laboratory in

southern France (Inovie Labosud, Montpellier, France). qPCR assays that screen for SARS-

CoV-2 variants were performed as recommended by French public health authorities

(https://www.data.gouv.fr/fr/datasets/donnees-de-laboratoires-pour-le-depistage-indicateurs-

sur-les-mutations/). In our center this included the detection of spike mutation among which

K417N (Thermo Fisher Scientific, Waltham, USA), combined with testing with the TaqPath

COVID-19 kit (Thermo Fisher Scientific) that target viral genes ORF1, N (nucleocapsid) and

S (spike), as previously reported.[3,28,29] The private medical laboratory used the ID SARS-

CoV-2/VOC Revolution Pentaplex assay (ID Solutions, Grabels, France) that detects spike

mutations K417N, L452R, and E484K (Pentaplex assay, ID Solution, France).

SARS-CoV-2 genomes were sequenced in the framework of genomic surveillance

implemented since February 2020[3] in our institute. Next-generation sequencing was

performed with the Illumina COVID-seq protocol on the NovaSeq 6000 instrument (Illumina

Inc., San Diego, CA, USA) or with the Oxford Nanopore technology (ONT) on a GridION

instrument (Oxford Nanopore Technologies Ltd., Oxford, UK) combined with prior multiplex

PCR amplification according to the ARTIC procedure (https://artic.network/), as previously

described,[3,28] with the ARTIC nCoV-2019 Amplicon Panel v4.1 of primers (IDT, Coralville,

IA, USA). Then, sequence read processing and genome analysis were performed as

previously described.[3,28] Briefly, for Illumina NovaSeq reads, base calling was performed

with the Dragen Bcl Convert pipeline [v3.9.3;

https://emea.support.illumina.com/sequencing/sequencing_software/bcl-convert.html

(Illumina Inc.)], mapping was performed with the bwa-mem2 tool (v. 2.2.1;

https://github.com/bwa-mem2/bwa-mem2) on the Wuhan-Hu-1 isolate genome (GenBank

accession no. NC_045512.2) then cleaned with Samtools (v. 1.13; https://www.htslib.org/),

variant calling was carried out with freebayes (v. 1.3.5;

https://github.com/freebayes/freebayes) and consensus genomes were built using Bcftools (v.

1.13; https://samtools.github.io/bcftools/bcftools.html). ONT reads were processed with the

ARTIC-nCoV-bioinformaticsSOP pipeline v1.1.0 (https://github.com/artic-

network/fieldbioinformatics). Nucleotide and amino acid changes relatively to the Wuhan-

Hu-1 isolate genome were obtained using the Nextclade tool

(https://clades.nextstrain.org/).[25,26] Nextstrain clades and Pangolin lineages were determined

using the Nextclade web application (https://clades.nextstrain.org/)[25,26] and the Pangolin tool

(https://cov-lineages.org/pangolin.html),[27] respectively. Genome sequences described here

were deposited in the GenBank sequence database (https://www.ncbi.nlm.nih.gov/genbank/)[30]

(OM990851, OM990852, OM991095, OM991295), and on the IHU Méditerranée Infection

website (https://www.mediterranee-infection.com/sars-cov-2-recombinant/). The Simplot

software (https://sray.med.som.jhmi.edu/SCRoftware/SimPlot/)[31] was used for recombination

analysis. Phylogeny was reconstructed by the IQTree (v2.1.3; http://www.iqtree.org/)[32] or

MEGA X[33] (v10.2.5; https://www.megasoftware.net/) tools and visualized with MEGA X

after sequence alignment with MAFFT (https://mafft.cbrc.jp/alignment/server/).[34] As

phylogenetic analysis can hardly applies to sequences that have different evolutionary

histories, we built two separate trees, a first one for the regions classified as of the Delta

21J/AY.4 variant (positions 1-22,128 and 25,519-29,903 in reference to the genome of the

Wuhan-Hu-1 isolate), and a second one for the regions classified as of the Omicron 21K/BA.1

variant (positions 22,129-25,519). The 10 genomes the closest genetically to these fragments

of the genome obtained here were selected through a BLAST[35] search among genomes of the

Delta 21J/AY.4 and Omicron 21K/BA.1 variants in the sequence database of our institute that

contains approximately 50,000 SARS-CoV-2 genomes; then, they were incorporated in the

phylogeny together with the genome of the Wuhan-Hu-1 isolate. As a matter of fact, it should

not be acceptable to make a phylogenetic tree based on concatenation of sequences from

different origin.

SARS-CoV-2 culture isolation was performed by inoculating 200 µL of respiratory

sample on Vero E6 cells as previously described.[36] Cytopathic effect was observed by

inverted microscopy. Viral particles were visualized in the culture supernatant by scanning

electron microscopy with a SU5000 microscope (Hitachi High-Technologies Corporation,

Tokyo, Japan), as previously described.[37]

Structural predictions of the spike protein were performed as previously

described.[28,38,39] Briefly, amino acid changes were introduced in the framework of a complete

14-1,200 structure of the original SARS-CoV-2 20B spike and missing amino acids were

incorporated with the Robetta protein structure prediction tool (https://robetta.bakerlab.org/)

before energy minimization through the Polak-Ribière algorithm.

A in house duplex qPCR assay specific of the SARS-CoV-2 recombinant was

designed that targets the genomes of the Delta 21J [targeted mutation: A11201G in the Nsp6

gene (corresponding to amino acid substitution T77A)] and the Omicron 21K/BA.1 [targeted

mutations: A23040G, G23048A, A23055G in the spike gene (Q493R, G496S, Q498R)]

variants. The sequences of the primers and probes (in 5'-3' orientation) are as follows: (i) for

the Delta 21J-targeting system: forward primer, CTGCTTTTGCAATGATGTTTGT; reverse

primer, TACGCATCACCCAACTAGCA; probe, 6FAM-

CTTGCCGCTGTAGCTTATTTTAAT (primers and probe concentrations in the mix were

200 nM and 150 nM, respectively); (ii) for the Omicron 21K/BA.1-targeting system: forward

primer, CCTTGTAATGGTGTTGAAGGTTTT; reverse primer,

CTGGTGCATGTAGAAGTTCAAAAG; probe, 6VIC-

TTTACGATCATATAGTTTCCGACCC (primers and probe concentrations in the mix were

250 nM and 200 nM, respectively).

This study was approved by the ethics committee of University Hospital Institute

Méditerranée Infection (No. 2022-001).

Results

The three case-patients were SARS-CoV-2-diagnosed on nasopharyngeal samples

collected in February 2022. Cycle threshold values (Ct) of diagnostic qPCR were between 20-

21. The patients were below 40 years of age. They resided in southern France and did not

travel abroad recently. They presented mild respiratory symptoms. Two were vaccinated

against SARS-CoV-2 (with two or three doses administered). Variant screening qPCR for the

2 samples collected in our institute showed positivity for the K417N mutation while the

TaqPath COVID-19 kit provided positive signals for all three genes targeted (ORF1, S, and

N). The third sample showed positivity for the K417N mutation and negativity for the L452R

and E484K mutations. Thus, overall, qPCR carried out on the three samples were indicative

of a Omicron variant.

The three viral genomes [GenBank Accession no. OM990851, OM990852,

OM991095 (https://www.ncbi.nlm.nih.gov/genbank/)[30]; available on the IHU Méditerranée

Infection website (https://www.mediterranee-infection.com/sars-cov-2-recombinant/)] were

hybrids of Delta 21J/AY.4 and Omicron 21K/BA.1 variant genomes (**Figures 1a, b, c; Table**

1). At positions harboring mutations compared to the genome of the Wuhan-Hu-1 isolate,

mean sequencing depth was between 1,163-1,421 reads and mean prevalence of the

majoritary nucleotide was between 99.4-99.9% (with minimum values between 80.3-98.7%),

ruling out the concurrent presence of two variants in the samples either due to co-infection or

to contamination. In this SARS-CoV-2 recombinant, most of the spike gene was replaced in a

Delta 21J/AY.4 matrix by an Omicron 21K/BA.1 sequence (**Figures 1a, b, c**). Indeed, the

recombination sites were located between nucleotide positions 22,034 and 22,194 for the first

one, and between nucleotide positions 25,469 and 25,584 for the second one. These regions

corresponds to amino acids 158 to 211 of the spike protein and to amino acids 26 to 64 of the

ORF3a protein whose gene is contiguous to the spike gene. The Simplot recombination

analysis tool provided congruent results.

Genomes from two of the three patients were identical and clustered in the

phylogenetic analysis (**Figures 1d, e**) despite no epidemiological link was documented

between these two patients. The third genome exhibited 5 nucleotide differences.

Phylogenetic analyses showed that most of the recombinant genomes was most closely related

to Delta 21J/AY.4 variant genomes identified in our institute, while the region spanning a

large part of their spike gene was most closely related to Omicron 21K/BA.1 variant genomes

identified in our institute.

The respiratory sample from which the first recombinant genome was obtained was

inoculated on Vero E6 cells the day following recombinant identification, and cytopathic

effect was observed after 4 days (**Figures 2a, b**; collection of strains of IHU Méditerranée

Infection, no. IHUMI-6070VR). The same day, supernatant was collected and next-generation

genome sequencing was performed using Nanopore technology on a GridION instrument

after PCR amplification with Artic primers, which allowed obtaining the genome sequence of

the viral isolate 8 h later [GenBank Accession no. OM991295

(https://www.ncbi.nlm.nih.gov/genbank/)[30]; available on the IHU Méditerranée Infection

website (https://www.mediterranee-infection.com/sars-cov-2-recombinant/)]. At mutated

positions compared to the Wuhan-Hu-1 isolate genome, mean sequencing depth was 2,771

reads and mean prevalence of the majoritary nucleotide was 99.1% (minimum, 95.1%), and

the consensus genome was identical to that obtained from the respiratory sample, showing

unambiguously that the virus isolated was the Delta 21J/AY.4-Omicron 21K/BA.1

recombinant. Finally, viral particles were observed in the culture supernatant by scanning

electron microscopy with a SU5000 microscope within minutes after supernatant collection

(**Figure 2c**).

The overall structure of the recombinant spike protein was predicted (**Figures 3a-c**).

When superimposed with the spike of the Omicron 21K/BA.1 variant, the main structural

changes were located in the N-terminal domain (NTD). In this region, the surface of the

recombinant spike protein is enlarged, flattened, and more electropositive, a property that is

characteristic of the Delta 21J/AY.4 NTD (**Figure 3c**). In the initial interaction of the virus

with the plasma membrane of the host cells, the NTD is attracted by lipid rafts, which

provides an electronegative landing platforms for the spike.[38,39] Thus, an increase in the

electrostatic surface of the NTD is expected to accelerate the binding of the virus to lipid rafts,

which may confer a selective kinetic advantage against virus competitors.[38] The receptor

binding domain (RBD) of the recombinant is clearly inherited from the Omicron 21K/BA.1

variant (**Figure 3c**). The consequence is also an increase in the electrostatic surface potential

of the RBD, which may facilitate the interaction with the electronegative interface of the

ACE-2 cellular receptor. Overall, this structural analysis suggests that the recombinant virus

could have been selected on the basis of kinetic properties conferred by a convergent increase

of the electrostatic potential of both the NTD and the RBD, together with an enlargement of

the NTD surface, all features that suggest an optimization of virus binding to the host cell

membrane.

Currently used qPCR screening assays were not able to discriminate this Delta

21J/AY.4-Omicron 21K/BA.1 recombinant and the Omicron 21K/BA.1 variant because the

Delta variant signature mutation detected is absent from the recombinant genome. Therefore,

we attempted to promptly implement a specific qPCR assay that could be used to detect the

recombinant for routine diagnosis use. This was achieved in one day by selecting qPCR

systems from our toolbox of dozens of in house qPCR systems that were designed since the

emergence of the first variant during summer 2020 to specifically target SARS-CoV-2

variants or mutants.[3,40] Two systems that target either the Delta 21J variant or the Omicron

BA.1 variant were combined in a duplex qPCR that can screen for the recombinant. In

preliminary assessment, both tested recombinant-positive samples were positive for the Delta

21J and Omicron BA.1 targets. In addition, 7 Delta non-21J-positive samples were negative

for both targets, 4 Delta 21J-positive samples were positive for the Delta 21J target but

negative for the Omicron BA.1 target, and 3 Omicron BA.1-positive samples were negative

for the Delta 21J target but positive for the Omicron BA.1 target.

Discussion

It is increasingly demonstrated that the genomes of most biological entities, whatever

their level of complexity, are mosaics of sequences from various origins.[41-45] The present

observations show us in real life the recombination potential of SARS-CoV-2, already largely

established for other coronaviruses.[4-6,8,46] and reported or suspected for SARS-CoV-2.[10,12,14-24]

SARS-CoV-2 recombinations were difficult to spot when only genetically very similar

viruses were circulating, as was the case in Europe during the first epidemic episode with

mutants derived from the Wuhan-Hu-1 virus. The increasing genetic diversity of SARS-CoV-

2, the tremendous number of infections at global and national levels, and the unprecedented

global effort of genomic sequencing (https://covariants.org/per-country),[3,25,47] raised the

probability of detecting recombinants. Such observations will probably make it possible in the

short or medium term to assess the recombination rate of SARS-CoV-2, whether there are

recombination hotspots, and to what extent recombinations between different variants can

generate new viable, and epidemic variants. This questions on the impact of recombinations

on viral replication and transmissibility, and on clinical severity, as well as on the virus ability

to escape neutralizing antibodies elicited by vaccines or a previous infection. In this view,

culture isolation of SARS-CoV-2 recombinants as was carried out here for the first time to

our knowledge is of primary importance. This variant mentioned recently has no known

epidemic potential. This will allow studying their phenotypic properties, among which their

replicative capacity in various cell lines, their sensitivity to antibodies, or their genetic

evolution *in vitro*. Concurrently, a high level of genomic surveillance must be maintained in

order to detect and characterize all recombination events and circulating recombinants, which

is a critical scientific and public health issue.

Acknowledgments

We are very grateful to Clio Grimaldier, Rita Zgheib, Claudia Andrieu, Ludivine Bréchard,

Raphael Tola, Anthony Fontanini, and Jacques Bou Khalil for their technical help.

Author contributions

Study conception and design: Philippe Colson, Pierre-Edouard Fournier, Jacques Fantini,

Didier Raoult, Bernard La Scola. Materials, data and analysis tools: Philippe Colson, Pierre-

Edouard Fournier, Jeremy Delerce, Matthieu Million, Marielle Bedotto, Linda Houhamdi,

Nouara Yahi, Jeremy Bayette, Jacques Fantini. Data analyses: Philippe Colson, Pierre-

Edouard Fournier, Jeremy Delerce, Marielle Bedotto, Anthony Levasseur, Jacques Fantini,

Didier Raoult, Bernard La Scola. Writing of the first draft of the manuscript: Philippe Colson,

Jacques Fantini, and Pierre-Edouard Fournier. All authors read, commented on, and approved

the final manuscript.

Funding

This work was supported by the French Government under the "Investments for the Future"

program managed by the National Agency for Research (ANR), Méditerranée-Infection 10-

IAHU-03; by Région Provence Alpes Côte d'Azur and European funding FEDER PRIMMI

(Fonds Européen de Développement Régional-Plateformes de Recherche et d'Innovation

Mutualisées Méditerranée Infection), FEDER PA 0000320 PRIMMI; by Hitachi High-

Technologies Corporation, Tokyo, Japan; and by the French Ministry of Higher Education,

Research and Innovation (ministère de l'Enseignement supérieur, de la Recherche et de

l'Innovation) and the French Ministry of Solidarity and Health (Ministère des Solidarités et de

la Santé).

Data availability

The dataset generated during the current study is available from the GenBank database

(https://www.ncbi.nlm.nih.gov/genbank/)[30] (GenBank Accession no. OM990851, OM990852,

OM991095, OM991295) and from the IHU Méditerranée Infection website

(https://www.mediterranee-infection.com/sars-cov-2-recombinant/).

Conflicts of interest

Didier Raoult has a conflict of interest as having been a consultant for Hitachi High-

Technologies Corporation, Tokyo, Japan from 2018 to 2020. He is a scientific board member

of Eurofins company and a founder of a microbial culture company (Culture Top). All other

authors have no conflicts of interest to declare. Funding sources had no role in the design and

conduct of the study; collection, management, analysis, and interpretation of the data; and

preparation, review, or approval of the manuscript.

Ethics

This study has been approved by the ethics committee of the University Hospital Institute

Méditerranée Infection (No. 2022-001). Access to the patients' biological and registry data

issued from the hospital information system was approved by the data protection committee

of Assistance Publique-Hôpitaux de Marseille (APHM) and was recorded in the European

General Data Protection Regulation registry under number RGPD/APHM 2019-73.

REFERENCES

1.   Lemey P, Ruktanonchai N, Hong SL, et al. Untangling introductions and persistence in

COVID-19 resurgence in Europe. *Nature*. 2021;595:713-717.

2.   Hodcroft EB, Zuber M, Nadeau S, et al.. Emergence and spread of a SARS-CoV-2

variant through Europe in the summer of 2020. *Nature*. 2021;595:707-712.

3.   Colson P, Fournier PE, Chaudet H, et al. Analysis of SARS-CoV-2 variants from

24,181 patients exemplifies the role of globalization and zoonosis in pandemics. *Front*

Microbiol. 2022b;12:786233.

4.   Lai MMC. Recombination in large RNA viruses: Coronaviruses. *Semin Virol.*

1996;7:381-388.

5.   Zhang Y, Li J, Xiao Y, et al. Genotype shift in human coronavirus OC43 and

emergence of a novel genotype by natural recombination. *J Infect.* 2015;70:641-50.

6.   Xiao Y, Rouzine IM, Bianco S, et al. RNA recombination enhances adaptability and is

required for virus spread and virulence. *Cell Host Microbe*. 2017;22:420.

7.   So RTY, Chu DKW, Miguel E, et al. Diversity of dromedary camel coronavirus

HKU23 in African camels revealed multiple recombination events among closely

related betacoronaviruses of the subgenus Embecovirus. *J Virol.* 2019;93:e01236-19.

8.   Gribble J, Stevens LJ, Agostini ML, et al. The coronavirus proofreading

exoribonuclease mediates extensive viral recombination. *PLoS Pathog.*

2021;17(1):e1009226.

9.   Bentley K, Evans DJ. Mechanisms and consequences of positive-strand RNA virus

recombination. *J Gen Virol.* 2018;99:1345-1356.

10.   Jackson B, Boni MF, Bull MJ, et al. Generation and transmission of interlineage

recombinants in the SARS-CoV-2 pandemic. *Cell.* 2021;184:5179-5188.e8.

11. Francisco RDS Jr, Benites LF, Lamarca AP, et al. Pervasive transmission of E484K and

emergence of VUI-NP13L with evidence of SARS-CoV-2 co-infection events by two

different lineages in Rio Grande do Sul, Brazil. *Virus Res*. 2021;296:198345.

12. Taghizadeh P, Salehi S, Heshmati A, et al. Study on SARS-CoV-2 strains in Iran

reveals potential contribution of co-infection with and recombination between different

strains to the emergence of new strains. *Virology*. 2021;562:63-73.

13. Rockett, JD, Mailie G, Eby MS, et al. Co-infection with SARS-CoV-2 Omicron and

Delta Variants revealed by genomic surveillance. *medRxiv* 2022; 2022.02.13.22270755;

doi: https://doi.org/10.1101/2022.02.13.22270755.

14. Yi H. 2019 Novel coronavirus is undergoing active recombination. *Clin Infect Dis*.

2020;71:884-887.

15. Yeh TY, Contreras GP. Emerging viral mutants in Australia suggest RNA

recombination event in the SARS-CoV-2 genome. *Med J Aust*. 2020;213:44-44.e1.

16. VanInsberghe D, Neish AS, Lowen AC, Koelle K. Recombinant SARS-CoV-2

genomes are currently circulating at low levels. *bioRxiv* 2021;2020.08.05.238386. doi:

10.1101/2020.08.05.238386.

17. Gallaher WR. A palindromic RNA sequence as a common breakpoint contributor to

copy-choice recombination in SARS-COV-2. *Arch Virol*. 2020;165:2341-2348.

18. Haddad D, John SE, Mohammad A, et al. SARS-CoV-2: Possible recombination and

emergence of potentially more virulent strains. *PLoS One*. 2021;16:e0251368.

19. Makarenkov V, Mazoure B, Rabusseau G, Legendre P. Horizontal gene transfer and

recombination analysis of SARS-CoV-2 genes helps discover its close relatives and

shed light on its origin. *BMC Ecol Evol*. 2021;21:5.

20. Varabyou A, Pockrandt C, Salzberg SL, Pertea M. Rapid detection of inter-clade

recombination in SARS-CoV-2 with Bolotie. *Genetics*. 2021;218:iyab074.

21.   Leary S, Gaudieri S, Parker MD, et al. Generation of a novel SARS-CoV-2 sub-

367   genomic RNA due to the R203K/G204R variant in nucleocapsid: homologous

368   recombination has potential to change SARS-CoV-2 at both protein and RNA level.

369   *Pathog Immun.* 2021;6:27-49.

370   22.   Lohrasbi-Nejad A. Detection of homologous recombination events in SARS-CoV-2.

371   *Biotechnol Lett.* 2022 Jan 17:1–16. doi: 10.1007/s10529-021-03218-7. Epub ahead of

372   print.

373   23.   Kreier F. Deltacron: the story of the variant that wasn't. *Nature*. 2022;602:19.

374   24.   Ignatieva A, Hein J, Jenkins PA. Ongoing recombination in SARS-CoV-2 revealed

375   through genealogical reconstruction. *Mol Biol Evol*. 2022;39:msac028.

376   25.   Aksamentov I, Roemer C, Hodcroft EB, Neher RA. Nextclade: clade assignment,

377   mutation calling and quality control for viral genomes. *Zenodo* 2021. doi:

378   https://doi.org/10.5281/zenodo.5607694.

379   26.   Hadfield J, Megill C, Bell SM, et al. Nextstrain: real-time tracking of pathogen

380   evolution. *Bioinformatics*. 2018;34:4121-4123.

381   27.   Rambaut A, Holmes EC, O'Toole Á, et al. A dynamic nomenclature proposal for SARS-

382   CoV-2 lineages to assist genomic epidemiology. *Nat Microbiol.* 2020;5:1403-1407.

383   28.   Colson P, Delerce J, Beye M, et al. First cases of infection with the 21L/BA.2 Omicron

384   variant in Marseille, France. *medRxiv* 2022a; 2022.02.08.22270495; doi:

385   https://doi.org/10.1101/2022.02.08.22270495.

386   29.   Houhamdi L, Gautret P, Hoang VT, Fournier PE, Colson P, Raoult D. Characteristics of

387   the first 1119 SARS-CoV-2 Omicron variant cases, in Marseille, France, November-

388   December 2021. *J Med Virol.* 2022 Jan 20. doi: 10.1002/jmv.27613. Epub ahead of

389   print.

30. Sayers EW, Cavanaugh M, Clark K, Pruitt KD, Schoch CL, Sherry ST, Karsch-

Mizrachi I. GenBank. *Nucleic Acids Res.* 2022 Jan 7;50(D1):D161-D164.

31. Lole KS, Bollinger RC, Paranjape RS, Gadkari D, Kulkarni SS, Novak NG, Ingersoll R,

Sheppard HW, Ray SC. Full-length human immunodeficiency virus type 1 genomes

from subtype C-infected seroconverters in India, with evidence of intersubtype

recombination. J Virol. 1999 Jan;73(1):152-60.

32. Nguyen LT, Schmidt HA, von Haeseler A, Minh BQ. IQ-TREE: a fast and effective

stochastic algorithm for estimating maximum-likelihood phylogenies. Mol Biol Evol.

2015 Jan;32(1):268-74. doi: 10.1093/molbev/msu300. Epub 2014 Nov 3. PMID:

25371430; PMCID: PMC4271533.

33. Kumar S, Stecher G, Li M, Knyaz C, Tamura K. MEGA X: Molecular Evolutionary

Genetics Analysis across Computing Platforms. Mol Biol Evol. 2018 Jun 1;35(6):1547-

1549. doi: 10.1093/molbev/msy096. PMID: 29722887; PMCID: PMC5967553.

34. Katoh K, Misawa K, Kuma K, Miyata T. MAFFT: a novel method for rapid multiple

sequence alignment based on fast Fourier transform. Nucleic Acids Res. 2002 Jul

15;30(14):3059-66. doi: 10.1093/nar/gkf436. PMID: 12136088; PMCID: PMC135756.

35. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search

tool. *J Mol Biol.* 1990;215:403-10.

36. La Scola B, Le Bideau M, Andreani J, et al. Viral RNA load as determined by cell

culture as a management tool for discharge of SARS-CoV-2 patients from infectious

disease wards. *Eur J Clin Microbiol Infect Dis*. 2020;39:1059-1061.

37. Colson P, Lagier JC, Baudoin JP, Bou Khalil J, La Scola B, Raoult D. Ultrarapid

diagnosis, microscope imaging, genome sequencing, and culture isolation of SARS-

CoV-2. *Eur J Clin Microbiol Infect Dis.* 2020 Aug;39(8):1601-1603.

38. Fantini J, Yahi N, Azzaz F, Chahinian H. Structural dynamics of SARS-CoV-2 variants:

A health monitoring strategy for anticipating Covid-19 outbreaks. *J Infect.*

2021;83:197-206.

39. Fantini J, Yahi N, Colson P, Chahinian H, La Scola B, Raoult D. The puzzling

mutational landscape of the SARS-2-variant Omicron. *J Med Virol.* 2022 Jan 8. doi:

10.1002/jmv.27577. Epub ahead of print.

40. Bedotto M, Fournier PE, Houhamdi L, Colson P, Raoult D. Implementation of an in-

house real-time reverse transcription-PCR assay to detect the emerging SARS-CoV-2

N501Y variants. *J Clin Virol.* 2021;140:104868.

41. Raoult D. A viral grandfather: genomics in 2010 contradict Darwin's vision of

evolution. *Eur J Clin Microbiol Infect Dis.* 2011;30:935-6.

42. Merhej V, Raoult D. Rhizome of life, catastrophes, sequence exchanges, gene creations,

and giant viruses: how microbial genomics challenges Darwin. *Front Cell Infect*

Microbiol. 2012;2:113.

43. Feschotte C, Gilbert C. Endogenous viruses: insights into viral evolution and impact on

host biology. *Nat Rev Genet.* 2012;13:283-96.

44. Roux S, Enault F, Bronner G, Vaulot D, Forterre P, Krupovic M. Chimeric viruses blur

the borders between the major groups of eukaryotic single-stranded DNA viruses. *Nat*

Commun. 2013;4:2700.

45. Jacobs GS, Hudjashov G, Saag L, et al. Multiple deeply divergent Denisovan ancestries

in Papuans. *Cell.* 2019;177:1010-1021.e32.

46. Liu X, Shao Y, Ma H, et al. Comparative analysis of four Massachusetts type infectious

bronchitis coronavirus genomes reveals a novel Massachusetts type strain and evidence

of natural recombination in the genome. *Infect Genet Evol.* 2013;14:29-38.

47.   Hodcroft E. 2012. CoVariants: SARS-CoV-2 mutations and variants of interest.

Available from: https://covariants.org/.

 FIGURE LEGEND

Figure 1. Schematic of the SARS-CoV-2 Delta 21J/AY.4-Omicron 21K/BA.1

recombinant genome, and phylogenetic trees based on different regions of the

Deltamicron genome reflecting the origin of most of the viral genome from a Delta

21J/AY.4 variant and the origin of a region spanning a large part of the spike gene from

a Omicron 21K/BA.1 variant.

a: Map of the SARS-CoV-2 genome.

b: Schematic representation of parental and recombinant genomes.

c: Mutations in the three Delta 21J/AY.4-Omicron 21K/BA1 recombinant genomes. Adapted

from screenshots of the nextclade web application output (https://clades.nextstrain.org).[25,26]

Color codes for nucleotide mutations and are marked regions as follows: Green: U; yellow: G;

blue: C; red: A; grey: deletions or uncovered regions. Genomes are labelled with the

identifiers of the IHU Méditerranée Infection and the GenBank

(https://www.ncbi.nlm.nih.gov/genbank/)[30] sequence databases.

d, e: Phylogenetic trees based on different regions of the Deltamicron genomes showing the

origin of most of the viral genome from a Delta 21J/AY.4 variant (d) and the origin of a

region spanning a large part of the spike gene from a Omicron 21K/BA.1 variant (e). The 10

genomes the most similar genetically to these regions of the recombinant genomes obtained

here were selected from the sequence database of our institute through a BLAST[35] search,

then were incorporated in the phylogeny together with the genome of the Wuhan-Hu-1

isolate. Sequences are labelled with the identifiers of the IHU Méditerranée Infection and the

GenBank (https://www.ncbi.nlm.nih.gov/genbank/)[30] sequence databases.

Figure 2. Microscopy images of the virus cytopathic effect (a, b) and of a viral particle

(c) in culture of the SARS-CoV-2 Delta 21J/AY.4-Omicron 21K/BA.1 recombinant on

Vero E6 cells.

a. Absence of cytopathic effect (negative control: absence of virus); b. Cytopathic effect

observed 4 days post-inoculation on Vero E6 cells of the respiratory sample of the first patient

for whom the SARS-CoV-2 Delta 21J/AY.4-Omicron 21K/BA.1 recombinant was identified.

c. Scanning electron microscopy image was obtained with a SU5000 microscope (Hitachi

High-Technologies Corporation, Tokyo, Japan).

Figure 3. Schematic of the predicted structure of the spike protein of the SARS-CoV-2

Delta 21J/AY.4-Omicron 21K/BA.1 recombinant

a. Overall structure of the recombinant spike protein. The secondary structure is in grey,

mutated amino acids are in blue. NTD, N-terminal domain; RBD, receptor binding domain;

S1-S2, cleavage site.

b. Superimposition of the secondary structure of the Omicron 21K/BA.1 variant (in cyan) and

recombinant (in red) spike proteins. NTD, N-terminal domain; RBD, receptor binding

domain.

c. Comparison of the electrostatic surface potential of the spike proteins in Delta 21J/AY.4

lineage, Omicron 21K/BA.1 variant, and in the recombinant. The color scale (negative in red,

positive in blue, neutral in white) is indicated. NTD, N-terminal domain; RBD, receptor

binding domain.

Table 1. Nucleotide and amino acid changes in the Deltamicron recombinant according to their presence/absence in the Delta 21J/AY.4 lineage and the Omicron 21K/BA.1 variant.

SARS-CoV-2 genes or genome regions	Nucleotide changes	Amino acid changes	Present in the Delta 21J/AY.4 lineage	Present in the Omicron 21K/BA.1 variant	Present in the Delta 21J/AY.4-Omicron 21K/BA.1 recombinant
5UTR	G210U	/	X		X
5UTR	C241U	/	X	X	X
ORF1a	A1321C	E352D			X
ORF1a	C3037U	/	X	X	X
ORF1a	G4181U	A1306S	X		X
ORF1a	C6402U	P2046L	X		X
ORF1a	C7124U	P2287S	X		X
ORF1a	C7851U	A2529V	X		X
ORF1a	A8723G	I2820V			X
ORF1a	C8986U	/	X		X
ORF1a	G9053U	V2930L	X		X
ORF1a	C10029U	T3255I	X	X	X
ORF1a	A11201G	T3646A	X		X
ORF1a	A11332G	/	X		X
ORF1b	C14407U	P314F / P314L			X
ORF1b	C14408U	P314F / P314L	X	X	X
ORF1b	U15264C	/	X		X
ORF1b	G15451A	G662S	X		X
ORF1b	C16466U	P1000L	X		X
ORF1b	C19220U	A1918V	X		X
S	C21618G	T19R	X		X
S	G21641U	A27S			X
S	C21846U	T95I	X	X	X
S	G21987A	G142D	X		X
S	GAGUUCA22028G	EFR156G	X		X
S	AAUU22193A	NL211I		X	X
S	U22204UGAGCCAGAA	Ins214EPE		X	X
S	G22578A	G339D		X	X
S	UC22673CU	S371L		X	X
S	U22679C	S373P		X	X
S	C22686U	S375F		X	X
S	G22813U	K417N		X	X
S	U22882G	N440K		X	X
S	G22898A	G446S		X	X
S	G22992A	S477N		X	X
S	C22995A	T478K	X	X	X
S	A23013C	E484A		X	X
S	A23040G	Q493R		X	X
S	G23048A	G496S		X	X
S	A23055G	Q498R		X	X
S	A23063U	N501Y		X	X
S	U23075C	Y505H		X	X
S	C23202A	T547K		X	X
S	A23403G	D614G	X	X	X
S	C23525U	H655Y		X	X
S	U23599G	N679K		X	X
S	C23604A	P681H		X	X
S	C23854A	N764K		X	X
S	G23948U	D796Y		X	X
S	C24130A	N856K		X	X
S	A24424U	Q954H		X	X
S	U24469A	N969K		X	X
S	C24503U	L981F		X	X
S	C25000U	/		X	X
ORF3a	C25667U	S92L			X
ORF3a	G25855U	D155Y			X
M	U26767C	I82T	X		X
ORF7a	U27638C	V82A	X		X
ORF7a	C27752U	T120I	X		X
ORF7b	C27874U	T40I	X		X
ORF8	AGAUUUC28247A	DF119Del	X		X
Intergenic region	UA28270U	/	X		X
N	A28461G	D63G	X		X
N	G28881U	R203M	X		X
N	G28916U	G215C	X		X
N	G29402U	D377Y	X		X
Intergenic region	G29540A	/			X
ORF10	G29645U	/			X
3UTR	G29742U	/	X		X

/, no change; Ins, insertion; Del, deletion; UTR, untranslated region; X, present. S gene region is indicated by a grey background.

Fig. 1

a. Map of the SARS-CoV-2 genome

b. Schematic of parental and recombinant genomes

Parental Delta 21J AY.4 genome

Delta 21J AY.4 - Omicron 21K/BA1 recombinant genomes

Parental Omicron 21K/BA.1 genome

c. Nucleotide mutations in the three Delta 21J AY.4 / Omicron 21K/BA1 recombinant genomes

relatively to Wuhan-Hu-1 isolate genome

IHUCOVID-64762 - OM990851
IHUCOVID-65147 - OM991095
IHUCOVID-65148 - OM990852

relatively to Delta 21J AY.4 variant genome

IHUCOVID-64762 - OM990851
IHUCOVID-65147 - OM991095
IHUCOVID-65148 - OM990852

relatively to Omicron 21K/BA.1 variant genome

IHUCOVID-64762 - OM990851
IHUCOVID-65147 - OM991095
IHUCOVID-65148 - OM990852

d. Phylogeny based on the recombinant genomes excluding their Omicron 21K/BA.1 region

e. Phylogeny based on the Omicron 21K/BA.1 region of the recombinant genomes

Fig. 2

a.

b.

c.

SU5000 10.0kV 5.5mm x25.0k SE(L)　　　　　　　　2.00μm

Fig. 3

a.

NTD

E156/F157⁻

T19R

RBD

N211⁻

S477N

S1-S2 →

Recombinant spike

b.

NTD   RBD

Omicron: cyan
Recombinant: red

c.

Small surface

Larger surface

NTD   RBD   NTD   RBD   NTD   RBD

Electronegative
area

Increased
surface
potential

+
-

Delta
21J AY.4

Omicron
BA.1

Recombinant
Delta/Omicron